In this issue:
Novel immunotherapy combo active in MSS mCRC
Earlier initiation of adjuvant chemotherapy has a DFS benefit
TransMet: liver transplantation feasible in select patients with unresectable CLM
Organ preservation possible with camrelizumab + apatinib in dMMR disease
Effectiveness of encorafenib-cetuximab for BRAF-mutated mCRC
FLOX + nivolumab may prolong PFS in specific subgroups with MSS mCRC
ICIs particularly efficacious in POLE/POLD1 proofreading-deficient mCRC
No benefit to FOLFOXIRI as conversion therapy for initially unresectable CLM
Front-line oxaliplatin/fluoropyrimidine/bevacizumab not suitable for geriatric patients
Can the interval to repeat colonoscopy after a negative result be extended?
Please login below to download this issue (PDF)